Exscientia plc (EXAI) said it will be expanding work with Amazon Web Services to use the cloud provider's artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia's platform, which is built using AWS technologies, supports its Design-Make-Test-Learn loops and spans generative AI, active learning, ML, physics-based systems and many other predictive methods.
"Extending our collaboration with AWS beyond our DesignStudio to include the robotic automation of synthesis and testing of our molecular designs was the logical next step for Exscientia," said John Overington, Chief Technology Officer of Exscientia.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.